Oncotelic lowers market cap milestone for Jefferson Capital from $100M to $45M

Oncotelic Therapeutics, Inc.

Amendment reduces first milestone threshold in independent contractor agreement from $100M to $45M market cap.
Contractor Jefferson Capital Ventures eligible to earn restricted stock upon achieving new $45M milestone.
Amendment aims to facilitate progress on equity line with Mast Hills, AGP financing, and uplisting.
No other terms of the milestone or ICA were changed.

item 1.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Oncotelic Therapeutics, Inc. amended ICA with Jefferson Capital Ventures, LLC (effective 2025-12-31).

Action: amendment
Counterparty: Jefferson Capital Ventures, LLC
Effective: 2025-12-31

Exact text from the filing

On December 31, 2025, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into an amendment to an independent contractor agreements (“ICA”) with Jefferson Capital Ventures, LLC (“Jefferson”) dated August 6, 2025, for modifying the threshold of the first milestone contained within the ICA.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Oncotelic Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-000619

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.